Thermo Fisher Unveils Integrated Platform to Advance Scalable Cell Therapy Manufacturing

The new system is expected to accelerate the development of cell therapies for cancer, autoimmune diseases, and other treatments.

Global medtech company, Thermo Fisher Scientific, has introduced the Gibco CTS DynaXS Single Use Bioreactor, a purpose-built expansion platform aimed at enabling cell therapy developers to scale manufacturing with precise control, flexibility, and regulatory readiness.

The newly launched system is intended to support flexible, cGMP-ready cell expansion from process development to clinical production. It is expected to accelerate the development of cell therapies for cancer, autoimmune, and other treatments.

The emerging applications of cell therapy often require different process configurations and production scales, adding complexity to manufacturing strategies across all stages of development and commercialization.

The CTS DynaXS Single Use Bioreactor seeks to address these evolving needs through a stirred-tank, single-use system, designed to support cell expansion across development and early clinical volumes.

It provides a seamless, scalable platform from small process development batches to larger cGMP manufacturing runs.

The CTS DynaXS bioreactor further strengthens Thermo Fisher’s Cell Therapy Systems (CTS) portfolio, supporting workflows from cell isolation and activation through expansion and downstream processing.

This integrated approach is expected to enable customers to build modular, scalable manufacturing strategies backed by unified technical support and regulatory documentation.

Commenting on the new rollout, Andy Campbell, Senior Director of Research and Development at Thermo Fisher Scientific, said, “With CTS DynaXS, we are providing a solution designed specifically for cell expansion that aligns with the broader cell therapy manufacturing journey. The single-use bioreactor offers a broad operating range and flexible design, enabling customers to efficiently scale from small to large production across a wide variety of volumes, applications, and cell types.”

Recently, the global medtech company launched the Applied Biosystems PowerFlex Thermal Cycler, a next-generation polymerase chain reaction (PCR) system designed to improve workflow efficiency in modern molecular biology laboratories.

The new instrument builds on the Applied Biosystems legacy of PCR technologies and is designed to provide enhanced flexibility, precise thermal control, and improved productivity in research and diagnostic settings.

Stay tuned for more such updates on Digital Health News